Details About Generic Salt ::  Testoste

Main Medicine Class:: Androgen   

(teh-STAHS-tuh-RONE)

Testosterone

Androderm, Histerone 100, Tesamone, Testandro, Testoderm, Testopel, Testoderm TTS, Testoderm with Adhesive

Testosterone Cypionate

depAndro 100, depAndro 200, Depo-Testosterone, Depotest 100, Depotest 200, Duratest-100, Duratest-200

Testosterone Enanthate

Andro L.A. 200, Andropository-200, Delatestryl, Durathate-200, Everone 200,  Malogen-LA, PMS-Testosterone Enanthate

Testosterone Propionate

Malogen in Oil

Class: Androgen

Drugs Class ::

 Action Promotes growth and development of male reproductive organs, maintains secondary sex characteristics, increases protein anabolism and decreases protein catabolism.

Indications for Drugs ::

 Indications

Men: Replacement therapy in primary hypogonadism and hypogonadotropic hypogonadism; stimulation of puberty in delayed puberty; treatment of impotence and male climacteric symptoms. Women: Ablation of ovaries in metastatic breast cancer; management of postpartum breast pain or engorgement. unlabeled use(S): Reversible contraception in men.

Drug Dose ::

 Route/Dosage

Androgen Replacement Therapy

ADULTS: IM 25–50 mg 2–3 times/wk (testosterone, testosterone propionate). IM 50–400 mg q 2–4 wk (testosterone enanthate, testosterone cypionate). SC 150–450 mg q 3 to 6 months. Transdermal 6 mg/day system applied daily or 4 mg/day system applied daily if scrotal area is small.

Delayed Puberty

ADOLESCENTS: IM 40–50 mg/m²/dose for 6 mo (testosterone, testosterone propionate) or IM 50–200 mg q 2–4 wk for limited duration (testosterone enanthate, testosterone cypionate) or IM 40–50 mg/m²/dose monthly until growth rate falls to prepubertal levels (testosterone, testosterone propionate). SC 150–450 mg q 4 to 6 months.

Breast Cancer

ADULTS: IM 50–100 mg 3 times weekly (testosterone, testosterone propionate) or IM 200–400 mg q 2–4 wk (testosterone enanthate, testosterone cypionate).

Postpartum Breast Engorgement

ADULTS: IM 25–50 mg per day for 3–4 days (testosterone, testosterone propionate).

Contraindication ::

 Contraindications Serious cardiac, hepatic or renal disease; men with carcinoma of breast or prostate; women who are or may become pregnant.

Drug Precautions ::

 Precautions

Pregnancy: Category X. Lactation: Undetermined. Children: Use drug with great caution; may effect bone maturation. Elderly patients: Elderly men may be at increased risk of developing prostatic hypertrophy or carcinoma. Acute intermittent porphyria: Has been reported. Use drug with caution in patients known to have this condition. Athletic performance: Abuse of these agents to enhance athletic performance has potential risk of serious side effects. Breast cancer and immobilized patients: May cause hypercalcemia. Edema: Use drug with caution in patients with conditions that might be affected by fluid retention (eg, asthma, cardiac or renal dysfunction, epilepsy). Gynecomastia: Frequently occurs and may persist. Use drug with caution in patients with preexisting gynecomastia. Hepatic effects: Prolonged use of high doses of androgens may result in potentially life threatening hepatitis, hepatic neoplasms or hepatocellular carcinoma. Oligospermia and reduced ejaculatory volume: May occur after prolonged use. Product interchange: Do not interchange products because of their differences in duration of action, especially testosterone cypionate and testosterone propionate. Serum cholesterol: Levels may increase with androgen use; use drug with caution in patients with history of MI or coronary artery disease.

Drug Side Effects ::

 Adverse Reactions

CV: Edema. CNS: Depression; headache; increased or decreased libido-anxiety. DERM: Acne; hirsutism; male pattern baldness; seborrhea; rash. GI: Nausea. GU: Men: Gynecomastia; penile erections; decreased ejaculatory volume. Women: Amenorrhea; virilization (deepening of voice and clitoral enlargement). HEPA: Cholestatic jaundice (elevated LFT results). META: Increased cholesterol; decreased serum glucose. OTHER: Inflammation at injection site; fluid and electrolyte retention.

Drug Mode of Action ::  

 Action Promotes growth and development of male reproductive organs, maintains secondary sex characteristics, increases protein anabolism and decreases protein catabolism.

Drug Interactions ::

 Interactions

Anticoagulants: May potentiate anticoagulant effects. Insulin, oral hypoglycemics: May decrease glucose levels and antidiabetic drug requirements. Oxyphenbutazone: Concurrent administration may result in elevated serum levels of oxyphenbutazone.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Determine if patient has serious cardiac, hepatic or renal disease, carcinoma of breast or prostate, clotting problems, epilepsy or migraine headaches.
• Monitor and record I&O. Notify physician of fluid retention.
• Report jaundice or inflamed injection site to physician.
• Monitor serum cholesterol and report to physician if total cholesterol has increased and is > 200 mg/dl.
• In male adolescents being treated for delayed puberty, monitor bone maturation by assessing bone age of the wrist and hand every 6 mo by x-ray evaluation.
• Perform periodic LFTS.
• Observe for hypercalcemia, especially in breast cancer patients and immobilized patients.
• Monitor for signs of virilization in women.
• Report frequent, persistent erections, nausea, vomiting and changes in skin color or ankle swelling.

Drug Storage/Management ::

 Administration/Storage

• Administer IM injections deep in gluteal muscle. Rotate sites.
• Shake vial well before withdrawing solution. Warming and shaking vial dissolves crystals that may have formed.
• Using wet needle or syringe may cause solution to become cloudy; however, this does not affect potency of drug.
• The number of pellets to be implanted depends upon the minimal daily requirement of testosterone propionate required weekly. Usual ratio is as follows: Implant two pellets for each 25 mg testosterone propionate required weekly. So when a patient requires injections of 75 mg per week, it is usually necessary to implant 450 mg (6 pellets). With injection of 50 mg per week, implantation of 300 mg (4 pellets) may suffice for approximately 3 months. With lower requirements by injection, correspondingly lower amounts may be implanted.
• Ascertain whether physician desires aqueous suspension or oil-based testosterone. Do not interchange products. Different salt forms have different duration of action.
• Wear gloves while handling transdermal patches. Apply transdermal patches to clean, dry and shaved scrotal skin. Patch should be worn 22–24 hr/day. Fold used patches with adhesive edges together. Discard patches so that they cannot be handled.
• Store IM preparation at room temperature.
• Store pellets in a cool place.

Drug Notes ::

 Patient/Family Education

• Caution patient that this medication must not be taken during pregnancy or when pregnancy is possible. Advise patient to use reliable form of birth control while taking this drug.
• Advise patient to consult with physician before taking otc or prescription drugs.
• Instruct patient to remain as active as possible. Hypercalcemia may result if patient is inactive and therapy will have to be discontinued.
• Advise patient to report these symptoms to physician: depression, headache, nausea, yellow skin or yellowing of whites of eyes, swelling of ankles, painful or difficult urination, severe acne or painful or prolonged penile erections.
• Inform patient of potential side effects: increased facial or body hair and loss of scalp hair (in both men and women), breast enlargement and decreased ejaculatory volume (in men) and deep voice, enlarged clitoris and cessation of menses (in women).
• Warn patients being treated for hypogonadism that gynecomastia caused by testosterone therapy may persist.
• Caution patient to neither take this drug without prescription nor increase prescribed dosage in effort to increase athletic performance. Side effects can be very serious.
• Instruct patient not to accept brands, types or forms of drug different from one originally prescribed.
• Advise patient using transdermal patches to wear briefs instead of boxer shorts underwear to keep the patch from falling off.
• Instruct patient using the transdermal scrotal patch to shave scrotum with dry disposable razor about once a week. Apply patch to dry scrotum. Patch should be temporarily removed while bathing or swimming. Patch is adhesive-free and clings to skin by an electrostatic effect.
• Male patients should have bone development checked every 6 months if receiving treatment for delayed puberty.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.